Notice of Effectiveness · EFFECT
XOMA Royalty Corporation
Notice of Effectiveness
Company context
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
Recent company filings
- SCHEDULE 13G/A - filed by MORGAN STANLEY regarding XOMA Royalty CorpAug 7, 2026
- SCHEDULE 13G/A - filed by MORGAN STANLEY regarding XOMA Royalty CorpAug 7, 2026
- SCHEDULE 13G/A - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding XOMA Royalty CorpJul 31, 2026
- SCHEDULE 13G/A - filed by BlackRock, Inc. regarding XOMA Royalty CorpJul 30, 2026
- 15-12G filingJul 27, 2026